NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR DISSEMINATION IN THE UNITED STATES SASKATOON, Saskatchewan & LONDON--(BUSINESS WIRE)--Gensource Potash Corporation (“Gensource” or the “Company”) (TSXV: GSP, AIM: GSP) is pleased to announce the
VANCOUVER, British Columbia--(BUSINESS WIRE)--Eat Well Investment Group Inc. (CSE: EWG) (US:EWGFF) (FSE: 6BC0) (“Eat Well” or the “Company”) is providing an update with respect to the expected timeline for filing its audited annual financial state
LAVAL, Quebec--(BUSINESS WIRE)--#Altasciences--Altasciences announced today that it has been awarded a 2022 CRO Leadership Award in five categories, marking the seventh year the CRO/CDMO has been deemed a top performer by Clinical Leader and Life Science
NIAGARA, Ontario--(BUSINESS WIRE)--extractX Ltd. (“extractX” or the “Company”), today announced financial results for the Company and its subsidiary extractX Incorporated (“EXI”) as at and for the three and six months ended March 31, 2022. All
WINNIPEG, Manitoba--(BUSINESS WIRE)--#agtech--TheoryMesh Corp, an innovative software company delivering data driven solutions for food and agriculture supply chains, today announced the launch of a project with Burcon NutraScience Corporation, a global t
Not for Distribution to U.S. Newswire Services or for Dissemination in the United States TORONTO--(BUSINESS WIRE)--Phoenix Canada Oil Company Limited (TSX-V: PCO) ("Phoenix") and ZYUS Life Sciences Inc. (“ZYUS” or the “Company”), a private Canadi
OTTAWA, Ontario--(BUSINESS WIRE)--Avivagen Inc. (TSXV:VIV, OTCQB:VIVXF) (“Avivagen”), a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that safely enhances feed intak
VANCOUVER, British Columbia & SEATTLE--(BUSINESS WIRE)--Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing next-generation multifunctional biotherapeutics, today announced that management will participate in an upcoming inv
Study of zanidatamab in combination with docetaxel results in 90.5% confirmed objective response rate (cORR) in first-line treatment of advanced HER2-positive breast cancer Zanidatamab in combination with chemotherapy and tislelizumab shows 75.8% cORR
– MOMENTUM data demonstrate potential use of momelotinib in myelofibrosis patients who are symptomatic and anemic – – Additional data highlight improved transfusion independence, symptoms and spleen volume of cytopenic myelofibrosis patients – S
Sign up for one of BAM's newsletter to learn more about bioscience, happenings in Manitoba's bioeconomy, industry conferences, and BAM training events.